INSTITUT PASTEUR D ALGERIE E.P.I.C.

Their core work

Institut Pasteur d'Algérie is Algeria's national public health reference laboratory, specializing in infectious disease surveillance, diagnostics, and biological sample collections for diseases endemic to North Africa. In H2020 projects, they contributed as a third-party expert — providing access to patient cohorts, biological specimens, and field expertise for diseases like bovine tuberculosis and leishmaniasis that are difficult to study without an in-country presence. Their scientific work spans from metabolomics-based breath diagnostics to molecular parasitology and immune profiling. For European consortia, they are the on-the-ground gateway to North African disease epidemiology and endemic sample collections that cannot be replicated in EU laboratory settings.

What they specialise in

How they've shifted over time

Both H2020 projects were launched in the same year (2018), so the evolution is more thematic than chronological: the earlier-listed project (bTB-Test) focused on non-invasive metabolomics and volatolomics for veterinary disease detection, while the second (LeiSHield-MATI, running until 2023) moved into molecular biology tools, immune response profiling, and even the psychological burden of chronic disease. This shift suggests IPA is expanding from sample-based analytical diagnostics toward systems-level disease understanding that integrates molecular data with clinical and social outcomes. The persistence of "biomarkers" across both projects confirms diagnostics as their stable core, while the methodological vocabulary grew significantly richer in the more recent work.

IPA appears to be deepening its infectious disease molecular toolkit — moving from physical sample analytics (breath, skin) toward transcriptomic and immunological methods — which positions them for future consortia targeting neglected tropical diseases and One Health research.

How they like to work

IPA has participated exclusively as a third party in H2020, meaning they contribute resources or expertise under another partner's umbrella rather than signing the grant agreement directly. This is typical of institutions in non-EU Associated Countries that provide endemic disease access, patient cohorts, or reference laboratory services to EU-led projects. Their 18 consortium partners across 11 countries, despite only 2 projects, indicates they were embedded in genuinely large international consortia — not small bilateral arrangements. Working with them requires routing their involvement through a primary EU partner, but the value they bring — access to North African disease populations — is otherwise unavailable to European teams.

Despite only two H2020 projects, IPA connected with 18 distinct consortium partners across 11 countries, reflecting participation in large multi-partner MSCA-RISE networks. Their geographic reach extends across Europe and into North Africa, consistent with their role bridging EU research with Algerian field sites.

What sets them apart

IPA is the only Algerian Pasteur Institute affiliate with H2020 project history in this database, making them the singular institutional bridge for EU consortia that need credible access to North African infectious disease cohorts, particularly for TB and leishmaniasis — both endemic in Algeria at a scale not found in EU member states. Their status as a national public health reference laboratory means they can provide not just samples but regulatory legitimacy, existing surveillance infrastructure, and clinical partnerships within Algeria. Consortia building projects on neglected tropical diseases or One Health themes affecting the Mediterranean and Sahel regions should consider IPA as a rare and difficult-to-replicate partner.

Highlights from their portfolio

• LeiSHield-MATI
  A long-running multi-disciplinary international effort (2018-2023) combining molecular biology, clinical science, and social impact assessment for leishmaniasis — one of the most comprehensive neglected tropical disease projects in H2020.
• bTB-Test
  Applied volatolomics and electronic nose technology to bovine TB diagnosis — an unusually hardware-forward diagnostic approach for a disease that costs European agriculture hundreds of millions annually.